Tesamorelin is a research compound. It is not approved by the FDA or any regulatory body for human use. This article is for educational and informational purposes only. Nothing here constitutes medical advice. Consult a qualified physician before considering any peptide use.
Tesamorelin (Synthetic GHRH analog (44 amino acid polypeptide)) is a GHRH analog, growth hormone secretagogue researched for visceral fat reduction, body image improvement, metabolic restoration in HIV lipodystrophy. Common dosages range from 2 mg daily administered once daily. Below are the most frequently asked questions.
Frequently Asked Questions About Tesamorelin
What is Tesamorelin?
Tesamorelin (Synthetic GHRH analog (44 amino acid polypeptide)) is a GHRH analog, growth hormone secretagogue. Synthetic 44 amino acid GHRH analog with enhanced metabolic stability and DPP-4 protease resistance. It is researched for visceral fat reduction, body image improvement, metabolic restoration in HIV lipodystrophy.
What is the recommended Tesamorelin dosage?
Common dosages range from 2 mg daily, administered once daily via subcutaneous injection. Cycles typically run ongoing maintenance; demonstrated benefit to 12+ months.
What are the side effects of Tesamorelin?
Well-tolerated. Injection site reactions most common. Transient flushing, headache, dizziness possible early on. No significant metabolic derangements.
Is Tesamorelin legal?
FDA-approved (2010) for HIV-associated lipodystrophy. Prescription medication.
What is the half-life of Tesamorelin?
The half-life of Tesamorelin is 26-38 minutes, which determines the once daily dosing schedule.
How do you reconstitute Tesamorelin?
Add bacteriostatic water to the lyophilized Tesamorelin vial. Let the water run down the side — never spray on the powder. Swirl gently. Use our peptide calculator for exact amounts.
Can you stack Tesamorelin with other peptides?
Combines with insulin-sensitizing agents for enhanced metabolic restoration. Off-label stacking with testosterone in HIV patients addresses complementary pathways.
Where can you buy Tesamorelin?
Tesamorelin is available as a research chemical from vetted suppliers with third-party COA testing.
How long does it take Tesamorelin to work?
Initial effects may be noticed within 1-2 weeks, with more significant results typically appearing by weeks 4-8 of a ongoing maintenance; demonstrated benefit to 12+ months cycle.
What makes Tesamorelin unique?
The most studied GHRH analog with the longest clinical track record — the only peptide with FDA approval specifically for lipodystrophy-associated visceral fat.
Complete Guide
Tesamorelin: The FDA-Approved GHRH Analog
Related Reading
- Tesamorelin Dosage Guide
- Tesamorelin Benefits
- Tesamorelin Side Effects
- Tesamorelin Stacking Guide
- Tesamorelin Cycle Guide
- Tesamorelin Research
Calculate Your Tesamorelin Dose
Use our free peptide dosing calculator to get exact reconstitution math and syringe units for Tesamorelin.
Open Calculator →Research-Grade Sourcing
If you're going to research Tesamorelin, source matters. These are the suppliers WolveStack has vetted for purity and third-party testing.
Frequently Asked Questions
What is Tesamorelin?
Tesamorelin (Synthetic GHRH analog (44 amino acid polypeptide)) is a GHRH analog, growth hormone secretagogue. Synthetic 44 amino acid GHRH analog with enhanced metabolic stability and DPP-4 protease resistance. It is researched for visceral fat reduction, body image improvement, metabolic restoration in HIV lipodystrophy.
What is the recommended Tesamorelin dosage?
Common dosages: 2 mg daily administered once daily via subcutaneous injection. Cycle length: ongoing maintenance; demonstrated benefit to 12+ months. Half-life: 26-38 minutes. Use our peptide calculator for exact reconstitution math.
What are the side effects of Tesamorelin?
Well-tolerated. Injection site reactions most common. Transient flushing, headache, dizziness possible early on. No significant metabolic derangements.
Is Tesamorelin safe?
Tesamorelin has shown a favorable safety profile in research. FDA-approved (2010) for HIV-associated lipodystrophy. Prescription medication. All research should follow appropriate safety protocols.